The quarter cleared the main earnings hurdle, but only narrowly. Non-GAAP diluted EPS was $0.71 versus published consensus of roughly $0.69, while revenue reached $228.2 million. The filing does not provide a dependable current revenue consensus, so the EPS comparison is the cleanest beat measure.
| Metric | Q2 2026 | Comparison / expectation |
|---|---|---|
| Revenue | $228.2M | $192.8M prior year; +18.3% YoY (Income Statement) |
| GAAP diluted EPS | $(0.32) | $(0.67) prior year (Income Statement) |
| Non-GAAP diluted EPS | $0.71 | Published consensus of approximately $0.69 |
| GAAP gross margin | 61.6% | 56.1% prior year (Income Statement) |
| Non-GAAP operating income | $26.8M | 11.8% of revenue (Non-GAAP Income Statement Items) |
| Operating cash flow, six months | $(9.6)M | $53.0M prior year (Cash Flow statement) |
| Inventory | $123.3M | $95.6M at January 3, 2026 (Balance Sheet) |
Underlying operating leverage was the strongest part of the release. Revenue rose 18% year over year and gross margin expanded to 61.6% from roughly 56%, while non-GAAP operating income reached $26.8 million, or 11.8% of sales (Income Statement; Non-GAAP Income Statement Items). That is a meaningful improvement from the prior-year operating loss, but the market was already expecting a sharp profitability recovery after first-quarter non-GAAP EPS of $0.53 and the company’s stated growth momentum.
The quality of the profit improvement is less clean than the headline suggests. GAAP still showed a $10.6 million operating loss, and the $23.8 million non-GAAP net profit excluded $25.6 million of stock compensation, $2.3 million of intangible amortization, and $9.5 million of merger-related costs (Non-GAAP Earnings Per Share). The adjustments are disclosed rather than hidden, but the size of the exclusions means reported GAAP earnings remain materially negative.
Cash generation deteriorated despite the earnings recovery. Silicon Labs used $9.6 million of operating cash during the first six months versus generating $53.0 million in the comparable period, as receivables and inventories absorbed cash; inventory also rose to $123.3 million from $95.6 million at the start of the year (Cash Flow statement; Balance Sheet). That does not negate the operating improvement, but it keeps the recovery from being a clean across-the-board beat.
The filing adds little new forward-looking information. Silicon Labs suspended formal guidance because of the pending Texas Instruments merger, so investors receive no fresh company forecast against which to measure the next quarter (Q1 2026 earnings release). Net: a modest earnings beat and clear margin improvement outweigh the weaker cash conversion, producing a narrow positive rather than a decisive upside signal.
Read the original 8-K on SEC EDGAR ↗